Objective of the study: To assess the outcome of Percutaneous coronary intervention in elderly in terms of success and complications. Methods: Retrospective data review of 887 consecutive cases of percutaneous interventions done at Karachi institute of heart diseases from 2015-2020. We divided the patients in three age groups younger (<65 years, n=592); older (65 to 75 years, n=201); and elderly (>=75 years, n=94). Immediate and six months outcomes of in hospital vascular complications, death, myocardial infarction, repeat target lesion revascularization and stroke were compared between these groups. Result: The vascular complications was in three groups (relative risk 3.2% vs 2.9% vs 4.3% with p=0.56) respectively. The relative risk of periprocedural Myocardial infarction in elderly/older patients was not higher than young patients with (OR of 0.6 with 95% CI 0.3 vs 1.4 with P=0.35), so was the need of repeat target revascularization with (OR of 0.3 95% CI 0.2 vs -1.6 with P=0.85), the risk of stroke following procedure was minimal (OR of 0.7 95% CI 0.4 vs 1.6 P=0.4). The in-hospital mortality was higher in elderly with (OR with 95% CI 1.0 vs 2.0 vs 3.4 P=0.03) in three groups. The six months outcomes of myocardial infarction in elderly were also not higher than younger pts (OR 0.7 vs 0.4 P=0.58). so was the need for repeat target revascularization (OR 0.5 vs 0.3 P=0.6). The six-month mortality in three groups was high in elderly (OR with 95% CI 1.5% vs 3.4% vs 4% with P value of 0.04). Conclusion: The procedure success in elderly patients was similar to younger patients, but in hospital and six months mortality was higher in elderlies.
目的:评价老年人经皮冠状动脉介入治疗的成功率和并发症。方法:回顾性分析卡拉奇心脏病研究所2015-2020年连续887例经皮介入治疗的资料。我们将患者分为三个年龄较小的组(75岁，n=94)。比较两组患者住院血管并发症、死亡、心肌梗死、重复靶区血管重建术和卒中的即时和6个月预后。结果:三组患者血管并发症发生率分别为3.2%、2.9%、4.3%，p=0.56。老年/老年患者围手术期心肌梗死的相对风险不高于年轻患者(OR为0.6,95% CI为0.3 vs . 1.4, P=0.35)，需要重复靶血运重建的患者(OR为0.3,95% CI为0.2 vs . -1.6, P=0.85)，手术后卒中的风险最小(OR为0.7,95% CI为0.4 vs . 1.6 P=0.4)。三组老年人住院死亡率均较高(95% CI 1.0 vs 2.0 vs 3.4 P=0.03)。老年患者心肌梗死6个月预后也不高于年轻患者(OR 0.7 vs 0.4 P=0.58)。重复目标血运重建术的需要也同样如此(OR 0.5 vs 0.3 P=0.6)。三组老年人6个月死亡率均较高(OR为95% CI 1.5% vs 3.4% vs 4%， P值为0.04)。结论:老年患者的手术成功率与年轻患者相似，但住院和6个月死亡率较高。
{"title":"Percutaneous Coronary Interventions in Elderly Patients: Experience from a Tertiary Care Center from Developing Country","authors":"","doi":"10.33140/coa.06.03.03","DOIUrl":"https://doi.org/10.33140/coa.06.03.03","url":null,"abstract":"Objective of the study: To assess the outcome of Percutaneous coronary intervention in elderly in terms of success and complications. Methods: Retrospective data review of 887 consecutive cases of percutaneous interventions done at Karachi institute of heart diseases from 2015-2020. We divided the patients in three age groups younger (<65 years, n=592); older (65 to 75 years, n=201); and elderly (>=75 years, n=94). Immediate and six months outcomes of in hospital vascular complications, death, myocardial infarction, repeat target lesion revascularization and stroke were compared between these groups. Result: The vascular complications was in three groups (relative risk 3.2% vs 2.9% vs 4.3% with p=0.56) respectively. The relative risk of periprocedural Myocardial infarction in elderly/older patients was not higher than young patients with (OR of 0.6 with 95% CI 0.3 vs 1.4 with P=0.35), so was the need of repeat target revascularization with (OR of 0.3 95% CI 0.2 vs -1.6 with P=0.85), the risk of stroke following procedure was minimal (OR of 0.7 95% CI 0.4 vs 1.6 P=0.4). The in-hospital mortality was higher in elderly with (OR with 95% CI 1.0 vs 2.0 vs 3.4 P=0.03) in three groups. The six months outcomes of myocardial infarction in elderly were also not higher than younger pts (OR 0.7 vs 0.4 P=0.58). so was the need for repeat target revascularization (OR 0.5 vs 0.3 P=0.6). The six-month mortality in three groups was high in elderly (OR with 95% CI 1.5% vs 3.4% vs 4% with P value of 0.04). Conclusion: The procedure success in elderly patients was similar to younger patients, but in hospital and six months mortality was higher in elderlies.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74922744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
All women face the threat of heart disease. Knowing the symptoms and risks unique to women, as well as eating a hearthealthy diet and exercising, can help protect you. Heart disease is often thought to be more of a problem for men. However, it’s the most common cause of death for both women and men in the United States. Because some heart disease symptoms in women can differ f Heart attack symptoms for women. The most common heart attack symptom in women is the same as in men some type of chest pain, pressure or discomfort that lasts more than a few minutes or comes and goes. But chest pain is not always severe or even the most noticeable symptom, particularly in women. Women often describe it as pressure or tightness. And, it’s possible to have a heart attack without chest pain. Women are more likely than men to have heart attack symptoms unrelated to chest pain, such as: Neck, jaw, shoulder, upper back or abdominal discomfort, Shortness of breath, Pain in one or both arms, Nausea or vomiting, Sweating, Lightheadedness or dizziness, unusual fatigue, Indigestion. These symptoms may be vague and not as noticeable as the crushing chest pain often associated with heart attacks. This might be because women tend to have blockages not only in their main arteries but also in the smaller ones that supply blood to the heart-a condition called small vessel heart disease or coronary microvascular disease. Women tend to have symptoms more often when resting, or even when asleep, than they do in men. Emotional stress can play a role in triggering heart attack symptoms in women. Because women don’t always recognize their symptoms as those of a heart attack, they tend to show up in emergency rooms after heart damage has occurred. Also, because their symptoms often differ from men’s, women might be diagnosed less often with heart disease than men are. If you have symptoms of a heart attack or think you’re having one, call for emergency medical help immediately. Don’t drive yourself to the emergency room unless you have no other options. Rom those in men, women often don’t know what to look for
{"title":"Heart Disease in Women","authors":"Targeted Key Messages","doi":"10.33140/coa.06.03.01","DOIUrl":"https://doi.org/10.33140/coa.06.03.01","url":null,"abstract":"All women face the threat of heart disease. Knowing the symptoms and risks unique to women, as well as eating a hearthealthy diet and exercising, can help protect you. Heart disease is often thought to be more of a problem for men. However, it’s the most common cause of death for both women and men in the United States. Because some heart disease symptoms in women can differ f Heart attack symptoms for women. The most common heart attack symptom in women is the same as in men some type of chest pain, pressure or discomfort that lasts more than a few minutes or comes and goes. But chest pain is not always severe or even the most noticeable symptom, particularly in women. Women often describe it as pressure or tightness. And, it’s possible to have a heart attack without chest pain. Women are more likely than men to have heart attack symptoms unrelated to chest pain, such as: Neck, jaw, shoulder, upper back or abdominal discomfort, Shortness of breath, Pain in one or both arms, Nausea or vomiting, Sweating, Lightheadedness or dizziness, unusual fatigue, Indigestion. These symptoms may be vague and not as noticeable as the crushing chest pain often associated with heart attacks. This might be because women tend to have blockages not only in their main arteries but also in the smaller ones that supply blood to the heart-a condition called small vessel heart disease or coronary microvascular disease. Women tend to have symptoms more often when resting, or even when asleep, than they do in men. Emotional stress can play a role in triggering heart attack symptoms in women. Because women don’t always recognize their symptoms as those of a heart attack, they tend to show up in emergency rooms after heart damage has occurred. Also, because their symptoms often differ from men’s, women might be diagnosed less often with heart disease than men are. If you have symptoms of a heart attack or think you’re having one, call for emergency medical help immediately. Don’t drive yourself to the emergency room unless you have no other options. Rom those in men, women often don’t know what to look for","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75472205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01DOI: 10.31487/j.jicoa.2021.04.01
M. Siercke, S. P. Møller, L. Thygesen, H. Sillesen, D. Overgaard
Aim: This study aimed to explore how qualitative data about rehabilitation for patients with intermittent claudication do provide an enhanced understanding of the quantitative experimental results. Background: The study was a randomized clinical trial comparing a rehabilitation intervention with usual care. A statistically significant difference between rehabilitation and usual care was found in walking distance, physical activity, quality of life and diet. The findings from the quantitative and qualitative analyses were analysed separately on their own tradition. In this study, mixed methods address whether the qualitative results could help explain the quantitative results and bring forward additional information. Design: Complex mixed-method intervention design with a convergent questionnaire variant. Methods: From April 2017- May 2019, patients diagnosed with intermittent claudication were included in a randomized clinical trial (N=118). In addition, qualitative interview informants from the intervention group were sampled from the quantitative study population for a survey (N=43) and focus group interviews (N=10). Interviews were conducted from April 2018-August 2019. Results: Integrated analyses identified how improvement in walking distance, physical activity, diet and quality of life was affected by team spirit, pedometer, education and fun exercise in a local setting. Quantitative and qualitative findings primarily confirmed and expanded each other; however, two discordant results were also evident. Conclusion: Our study adds empirical evidence regarding how a mixed-methods study can be used to obtain a more nuanced understanding of complex healthcare problems. The study provides new knowledge concerning how to set up a rehabilitation programme for patients with intermittent claudication.
{"title":"Improving Rehabilitation for Patients with Intermittent Claudication: A Randomized Controlled Trial with a Mixed-Methods Evaluation (The CIPIC Rehab Study)","authors":"M. Siercke, S. P. Møller, L. Thygesen, H. Sillesen, D. Overgaard","doi":"10.31487/j.jicoa.2021.04.01","DOIUrl":"https://doi.org/10.31487/j.jicoa.2021.04.01","url":null,"abstract":"Aim: This study aimed to explore how qualitative data about rehabilitation for patients with intermittent claudication do provide an enhanced understanding of the quantitative experimental results.\u0000Background: The study was a randomized clinical trial comparing a rehabilitation intervention with usual care. A statistically significant difference between rehabilitation and usual care was found in walking distance, physical activity, quality of life and diet. The findings from the quantitative and qualitative analyses were analysed separately on their own tradition. In this study, mixed methods address whether the qualitative results could help explain the quantitative results and bring forward additional information.\u0000Design: Complex mixed-method intervention design with a convergent questionnaire variant.\u0000Methods: From April 2017- May 2019, patients diagnosed with intermittent claudication were included in a randomized clinical trial (N=118). In addition, qualitative interview informants from the intervention group were sampled from the quantitative study population for a survey (N=43) and focus group interviews (N=10). Interviews were conducted from April 2018-August 2019.\u0000Results: Integrated analyses identified how improvement in walking distance, physical activity, diet and quality of life was affected by team spirit, pedometer, education and fun exercise in a local setting. Quantitative and qualitative findings primarily confirmed and expanded each other; however, two discordant results were also evident.\u0000Conclusion: Our study adds empirical evidence regarding how a mixed-methods study can be used to obtain a more nuanced understanding of complex healthcare problems. The study provides new knowledge concerning how to set up a rehabilitation programme for patients with intermittent claudication.\u0000","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42976454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a risk predictor for cardiovascular diseases (CVD). Generally, plasma Lp-PLA2 was thought to be secreted by circulatory inflammatory cells. Lp-PLA2 mRNA expression of PBMC may also be a risk predictor. Methods: A total of 104 subjects angiographically verified ACS patients were enrolled, including 73 unstable angina pectoris (UAP) patients and 31 acute myocardial infarction (AMI) patients. Plasma lipids, Lp-PLA2 activity and Lp-PLA2 mass were measured. Lp-PLA2 mRNA expression of PBMC was relatively quantified by real-time fluorescence PCR. Results: Plasma Lp-PLA2 activity was increased in AMI patients compared to UAP patients (395.21±145.91 vs. 328.53±127.03 U/L, p=0.024). Lp-PLA2 mass of AMI patients was also higher than UAP patients (136.43±45.46 vs. 119.16±44.19 ng/mL, p=0.093), while PBMC mRNA expression was not statistically different [1.07 (0.74, 1.57) vs. 0.88(0.49, 1.99), p=0.453]. Comparing Lp-PLA2 mRNA by groups, Lp-PLA2 mRNA level was higher in male ACS patients and smoking ACS patients (p=0.008, p=0.048, respectively). Multivariate logistic regression analysis showed that Lp-PLA2 activity was an AMI risk predictor (OR=5.224, 95% CI 1.687-16.181, p=0.004), after smoking, systolic blood pressure, diabetes and hyperlipidemia were adjusted. Recurrent ACS patients were older (p=0.035), but they showed lower levels of Lp-PLA2 mass and Lp-PLA2 activity (p=0.014, p=0.045, respectively), compared to primary ACS patients. Conclusion: Smoking may be an important regulatory factor for Lp-PLA2 mRNA expression in PBMC. Among three Lp-PLA2 indexes, Lp-PLA2 activity was the best marker indicating AMI risk, while Lp-PLA2 mass maybe play better role as a predictor in avoiding ACS recurrence.
{"title":"Comparison of Lp-PLA2 Activity, Lp-PLA2 Mass and Lp-PLA2 mRNA in Acute Coronary Syndrome Patients","authors":"Xu Ma, Yulong Li, Qi Sun, Ting Ding, L. Mu, Hui Yuan","doi":"10.31487/j.jicoa.2021.03.04","DOIUrl":"https://doi.org/10.31487/j.jicoa.2021.03.04","url":null,"abstract":"Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a risk predictor for cardiovascular diseases (CVD). Generally, plasma Lp-PLA2 was thought to be secreted by circulatory inflammatory cells. Lp-PLA2 mRNA expression of PBMC may also be a risk predictor.\u0000Methods: A total of 104 subjects angiographically verified ACS patients were enrolled, including 73 unstable angina pectoris (UAP) patients and 31 acute myocardial infarction (AMI) patients. Plasma lipids, Lp-PLA2 activity and Lp-PLA2 mass were measured. Lp-PLA2 mRNA expression of PBMC was relatively quantified by real-time fluorescence PCR.\u0000Results: Plasma Lp-PLA2 activity was increased in AMI patients compared to UAP patients (395.21±145.91 vs. 328.53±127.03 U/L, p=0.024). Lp-PLA2 mass of AMI patients was also higher than UAP patients (136.43±45.46 vs. 119.16±44.19 ng/mL, p=0.093), while PBMC mRNA expression was not statistically different [1.07 (0.74, 1.57) vs. 0.88(0.49, 1.99), p=0.453]. Comparing Lp-PLA2 mRNA by groups, Lp-PLA2 mRNA level was higher in male ACS patients and smoking ACS patients (p=0.008, p=0.048, respectively). Multivariate logistic regression analysis showed that Lp-PLA2 activity was an AMI risk predictor (OR=5.224, 95% CI 1.687-16.181, p=0.004), after smoking, systolic blood pressure, diabetes and hyperlipidemia were adjusted. Recurrent ACS patients were older (p=0.035), but they showed lower levels of Lp-PLA2 mass and Lp-PLA2 activity (p=0.014, p=0.045, respectively), compared to primary ACS patients.\u0000Conclusion: Smoking may be an important regulatory factor for Lp-PLA2 mRNA expression in PBMC. Among three Lp-PLA2 indexes, Lp-PLA2 activity was the best marker indicating AMI risk, while Lp-PLA2 mass maybe play better role as a predictor in avoiding ACS recurrence.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49130141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-15DOI: 10.31487/j.jicoa.2021.03.08
R. Bhandari, R. Wiener, Christopher Waters, Cassandra Bambrick
Patients with opioid use disorder are more likely to get coronavirus disease 2019 (COVID-19). Cardiovascular diseases frequently present in COVID-19 patients and can increase their susceptibility to invasive infectious diseases, such as infective endocarditis (IE). This study examines the difference in IE incidence following COVID-19 diagnosis between individuals with and without non-medical opioid use. De-identified electronic medical records data were retrieved from TriNetX, a web-based database. Patients in the U.S., aged 18-60 years, with a diagnosis of COVID-19 during January 2020 - January 2021 were included in this study. Development of IE was determined within three months after COVID-19 diagnosis. Logistic regression was conducted to estimate the risk of developing IE between COVID-19 patients with and without opioid use after propensity score matching. COVID-19 patients with non-medical opioid use had 6.8 times the risk of developing IE compared with COVID-19 patients without opioid use (95% CI: 5.44, 8.56; p<0.0001) after propensity score matching. Findings suggest a significant risk of IE among COVID-19 patients with a history of non-medical opioid use. It provides objective evidence to account for baseline opioid use in the risk assessment of IE among COVID-19 patients.
{"title":"The Risk of Infective Endocarditis among COVID-19 Patients with Non-Medical Opioid Use","authors":"R. Bhandari, R. Wiener, Christopher Waters, Cassandra Bambrick","doi":"10.31487/j.jicoa.2021.03.08","DOIUrl":"https://doi.org/10.31487/j.jicoa.2021.03.08","url":null,"abstract":"Patients with opioid use disorder are more likely to get coronavirus disease 2019 (COVID-19). Cardiovascular diseases frequently present in COVID-19 patients and can increase their susceptibility to invasive infectious diseases, such as infective endocarditis (IE). This study examines the difference in IE incidence following COVID-19 diagnosis between individuals with and without non-medical opioid use. De-identified electronic medical records data were retrieved from TriNetX, a web-based database. Patients in the U.S., aged 18-60 years, with a diagnosis of COVID-19 during January 2020 - January 2021 were included in this study. Development of IE was determined within three months after COVID-19 diagnosis. Logistic regression was conducted to estimate the risk of developing IE between COVID-19 patients with and without opioid use after propensity score matching. COVID-19 patients with non-medical opioid use had 6.8 times the risk of developing IE compared with COVID-19 patients without opioid use (95% CI: 5.44, 8.56; p<0.0001) after propensity score matching. Findings suggest a significant risk of IE among COVID-19 patients with a history of non-medical opioid use. It provides objective evidence to account for baseline opioid use in the risk assessment of IE among COVID-19 patients.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48998454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-13DOI: 10.31487/j.jicoa.2021.03.09
A. Ray, Shamsuzzaman, J. Joshi, K. Gulati
Methylxanthines are potent bronchodilators used in obstructive airway disease like COPD and bronchial asthma, but the narrow therapeutic index and resultant adverse effect profile have restricted their use. Novel beneficial effects and modes of action are now being proposed for these pharmacoeconomically viable agents. Cardiotoxicity is a prominent adverse effect of methylxanthone and thus we investigated possible mechanisms for such toxicity with an aim to devise ameliorative strategies for counteracting such undesirable effects. In view of the cardioprotective role of nitric oxide (NO) and NO mimetics, the present study investigated the possible modulatory role of L-arginine, a NO precursor, in theophylline induced cardiotoxicity in rats, with a view to exploring strategies for facilitating the safe use of this drug. The methylxanthine, aminophylline induced cardiotoxic effects like increased heart rat, raised mean BP, inverted T-waves and prolonged QTc interval (in ECG). These were accompanied by increased levels of cardiac biomarkers like Troponin-I, CPK-MB, and ADMA. Oxidative stress markers like MDA were elevated whereas, antioxidant defence markers like GSH and SOD were suppressed. Co-administration of L-arginine (with aminophylline) had dose-related effects on cardiac function (heart rate, mean BP, ECG changes) and cardiospecific biomarkers (TnI, CPK-MB, ADMA) - the lower dose being protective whereas the higher dose potentiating some of the cardiac effects and cardiospecific/oxidative stress biomarker levels. The results indicate a biphasic involvement of NO in the cardiotoxic effect of theophylline and suggests possible interactions of NO with reactive oxygen species during such modulations of cardiotoxicity.
{"title":"Modulatory Effects of L-Arginine on Methylxanthine-Induced Cardiotoxicity in Rats: A Differential Role for Nitric Oxide (NO)","authors":"A. Ray, Shamsuzzaman, J. Joshi, K. Gulati","doi":"10.31487/j.jicoa.2021.03.09","DOIUrl":"https://doi.org/10.31487/j.jicoa.2021.03.09","url":null,"abstract":"Methylxanthines are potent bronchodilators used in obstructive airway disease like COPD and bronchial asthma, but the narrow therapeutic index and resultant adverse effect profile have restricted their use. Novel beneficial effects and modes of action are now being proposed for these pharmacoeconomically viable agents. Cardiotoxicity is a prominent adverse effect of methylxanthone and thus we investigated possible mechanisms for such toxicity with an aim to devise ameliorative strategies for counteracting such undesirable effects. In view of the cardioprotective role of nitric oxide (NO) and NO mimetics, the present study investigated the possible modulatory role of L-arginine, a NO precursor, in theophylline induced cardiotoxicity in rats, with a view to exploring strategies for facilitating the safe use of this drug. The methylxanthine, aminophylline induced cardiotoxic effects like increased heart rat, raised mean BP, inverted T-waves and prolonged QTc interval (in ECG). These were accompanied by increased levels of cardiac biomarkers like Troponin-I, CPK-MB, and ADMA. Oxidative stress markers like MDA were elevated whereas, antioxidant defence markers like GSH and SOD were suppressed. Co-administration of L-arginine (with aminophylline) had dose-related effects on cardiac function (heart rate, mean BP, ECG changes) and cardiospecific biomarkers (TnI, CPK-MB, ADMA) - the lower dose being protective whereas the higher dose potentiating some of the cardiac effects and cardiospecific/oxidative stress biomarker levels. The results indicate a biphasic involvement of NO in the cardiotoxic effect of theophylline and suggests possible interactions of NO with reactive oxygen species during such modulations of cardiotoxicity.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49054475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-03DOI: 10.31487/j.jicoa.2021.03.07
A. Hadjizadeh, Minoo Alavi, Samira Tajvar
The emergence of recent viral outbreaks, especially the COVID-19 pandemic, and the resulting global mortality and damage has created an urgent need to accelerate the identification, prevention, and treatment of these viral diseases. Due to the limitations in the use of humans, and animal models in terms of time, costs, metabolism differences and ethical issues, in vitro models have become essential in virology research. In the present review, we collected the application of several used cell culture models in studies on four pathogenic viruses - severe acute respiratory syndrome coronavirus (SARS-CoV), influenza A virus (H1N1), middle east respiratory syndrome coronavirus (MERS-CoV), and 2019 novel coronavirus (SARS-CoV-2). These models included, 2D and 3D cell culture (organoids, microfluidic-chips, and bioprinted models). A collection of existing research on these viruses can help fight against the SARS-CoV-2 virus and speed it up against future emerging viruses. Moreover, it can show the shortcomings of in vitro models in virology studies that have been performed to date and provide researchers with new ideas for developing models that are more efficient to deal with similar viral outbreaks.
{"title":"Application of Cell Culture Models in Studying Viral Diseases (SARS, H1N1 Flu, MERS, COVID-19): A Review","authors":"A. Hadjizadeh, Minoo Alavi, Samira Tajvar","doi":"10.31487/j.jicoa.2021.03.07","DOIUrl":"https://doi.org/10.31487/j.jicoa.2021.03.07","url":null,"abstract":"The emergence of recent viral outbreaks, especially the COVID-19 pandemic, and the resulting global \u0000mortality and damage has created an urgent need to accelerate the identification, prevention, and treatment \u0000of these viral diseases. Due to the limitations in the use of humans, and animal models in terms of time, \u0000costs, metabolism differences and ethical issues, in vitro models have become essential in virology research. \u0000In the present review, we collected the application of several used cell culture models in studies on four \u0000pathogenic viruses - severe acute respiratory syndrome coronavirus (SARS-CoV), influenza A virus \u0000(H1N1), middle east respiratory syndrome coronavirus (MERS-CoV), and 2019 novel coronavirus (SARS-CoV-2). These models included, 2D and 3D cell culture (organoids, microfluidic-chips, and bioprinted \u0000models). A collection of existing research on these viruses can help fight against the SARS-CoV-2 virus \u0000and speed it up against future emerging viruses. Moreover, it can show the shortcomings of in vitro models \u0000in virology studies that have been performed to date and provide researchers with new ideas for developing \u0000models that are more efficient to deal with similar viral outbreaks.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47157087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-19DOI: 10.31487/j.jicoa.2021.03.05
C. D. C. Gordillo, F. Y. Vidal, F. A. Florit, Fernando Verdugo Thomas, A. Gonzales, Mario Alfaro Diaz
In the COVID-19 pandemic, we performed a series of echocardiograms using subcostal views. After placing a patient in a prone position during invasive mechanical ventilation, the echocardiogram transducer was placed under the patient in the left subcostal position. This performance allowed us to evaluate the function of the pulmonary valve and estimate pulmonary pressure. This is a complement to the monitoring with a transthoracic echocardiogram in the prone position.
{"title":"How to Evaluate the Pulmonary Valve and Right Ventricular Outflow Tract in Prone Position during Invasive Mechanical Ventilation","authors":"C. D. C. Gordillo, F. Y. Vidal, F. A. Florit, Fernando Verdugo Thomas, A. Gonzales, Mario Alfaro Diaz","doi":"10.31487/j.jicoa.2021.03.05","DOIUrl":"https://doi.org/10.31487/j.jicoa.2021.03.05","url":null,"abstract":"In the COVID-19 pandemic, we performed a series of echocardiograms using subcostal views. After placing a patient in a prone position during invasive mechanical ventilation, the echocardiogram transducer was placed under the patient in the left subcostal position. This performance allowed us to evaluate the function of the pulmonary valve and estimate pulmonary pressure. This is a complement to the monitoring with a transthoracic echocardiogram in the prone position.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43162600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-17DOI: 10.31487/j.jicoa.2021.02.03
Filip Wołoszyn, Krystian Mazur, Mateusz Mielniczuk, M. Kopańska
Biofeedback is defined as providing feedback about changes in the patient’s physiological state, by means of stimuli other than those used by the body, usually with the use of technology. This article presents an analysis based on the surveys regarding the awareness of Polish society about biological feedback and its effectiveness in the rehabilitation of patients with cardiac problems. The study was conducted to justify the use in the therapy on people with cardiac problems. The analysis of the patients results after cardiovascular diseases was carried out during the cardiac rehabilitation in which the biofeedback was used.
{"title":"Biofeedback As an Example of Modern Exercise Method Used in Cardiac Rehabilitation","authors":"Filip Wołoszyn, Krystian Mazur, Mateusz Mielniczuk, M. Kopańska","doi":"10.31487/j.jicoa.2021.02.03","DOIUrl":"https://doi.org/10.31487/j.jicoa.2021.02.03","url":null,"abstract":"Biofeedback is defined as providing feedback about changes in the patient’s physiological state, by means \u0000of stimuli other than those used by the body, usually with the use of technology. This article presents an \u0000analysis based on the surveys regarding the awareness of Polish society about biological feedback and its \u0000effectiveness in the rehabilitation of patients with cardiac problems. The study was conducted to justify the \u0000use in the therapy on people with cardiac problems. The analysis of the patients results after cardiovascular \u0000diseases was carried out during the cardiac rehabilitation in which the biofeedback was used.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48719006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-13DOI: 10.31487/j.jicoa.2021.03.06
Farhin Iqbal, B. Dutta, J. C. Barkataki, W. Farooqui, Arun Yadav
Background: Data on impact of gender on clinical presentation of ST Elevation Myocardial Infarction (STEMI) are sparse in our country. Gender related difference in STEMI has never been studied in North-Eastern India. Aim: The present study was undertaken to study the impact of gender on clinical characteristic, treatment and outcome in STEMI. Methods: We prospectively collected data of 510 STEMI patients from February 2011 to August 2012 in Gauhati Medical College, a tertiary care center in North-Eastern India. We evaluated data on impact of gender in clinical characteristic, treatment, and outcome in STEMI patients. Results: A total of 510 cases of STEMI were included. Females in STEMI were older (53.6 years in males compared to 58 years in females, P<0.001) and have greater atypical presentation (31.6% in females and 13.98% in males, P<0.001). Females also have higher mean time to presentation and higher incidence of diabetes, dyslipidemia, hypertension and high BMI, whereas males had higher incidence of smoking. Females are less likely to undergo thrombolysis (28.73% in females compared to 44.34% in males, p=0.04) and revascularization (17.5% in males and 9.1% in females p-0.01) during index hospitalization, but standard medical therapy was similar. Women were also more likely to develop heart failure either at presentation or at 30 days and also had a higher 30-day mortality (15.5% in female and 9.8% in male, p value-0.06). Conclusion: This study represents the first reported study on impact of gender on clinical presentation of STEMI from North-Eastern India and has observed that females have a higher mean age of presentation, higher incidence of atypical presentation, diabetes, dyslipidemia, hypertension and high BMI. Females also present later than males, though statistically not significant and also less likely to receive thrombolysis and revascularization than males. The 30-day mortality was also higher in females.
背景:在我国，性别对ST段抬高型心肌梗死(STEMI)临床表现影响的数据较少。STEMI的性别相关差异从未在印度东北部进行过研究。目的:本研究旨在探讨性别对STEMI患者临床特征、治疗及转归的影响。方法:前瞻性收集2011年2月至2012年8月印度东北部高哈蒂医学院(Gauhati Medical College)三级医疗中心510例STEMI患者的资料。我们评估了性别对STEMI患者临床特征、治疗和结局的影响。结果:共纳入STEMI 510例。STEMI患者的女性年龄较大(男性为53.6岁，女性为58岁，P<0.001)，非典型表现较多(女性为31.6%，男性为13.98%，P<0.001)。女性的平均发病时间也更长，糖尿病、血脂异常、高血压和高BMI的发病率也更高，而男性的吸烟率更高。在指数住院期间，女性接受溶栓(女性为28.73%，男性为44.34%，p=0.04)和血运重建术(男性为17.5%，女性为9.1%，p= 0.01)的可能性较低，但标准药物治疗相似。女性在就诊时或30天内更容易发生心力衰竭，30天死亡率也更高(女性为15.5%，男性为9.8%，p值为0.06)。结论:本研究首次报道了性别对印度东北部STEMI临床表现的影响，并观察到女性的平均表现年龄更高，非典型表现、糖尿病、血脂异常、高血压和高BMI的发生率更高。女性出现的时间也比男性晚，但在统计上不显著，而且接受溶栓和血运重建术的可能性也比男性低。女性的30天死亡率也更高。
{"title":"Impact of Gender on Clinical Characteristic, Treatment and Outcome in ST Elevation Myocardial Infarction: A Hospital Based Study from North-Eastern India","authors":"Farhin Iqbal, B. Dutta, J. C. Barkataki, W. Farooqui, Arun Yadav","doi":"10.31487/j.jicoa.2021.03.06","DOIUrl":"https://doi.org/10.31487/j.jicoa.2021.03.06","url":null,"abstract":"Background: Data on impact of gender on clinical presentation of ST Elevation Myocardial Infarction (STEMI) are sparse in our country. Gender related difference in STEMI has never been studied in North-Eastern India.\u0000Aim: The present study was undertaken to study the impact of gender on clinical characteristic, treatment and outcome in STEMI.\u0000Methods: We prospectively collected data of 510 STEMI patients from February 2011 to August 2012 in Gauhati Medical College, a tertiary care center in North-Eastern India. We evaluated data on impact of gender in clinical characteristic, treatment, and outcome in STEMI patients.\u0000Results: A total of 510 cases of STEMI were included. Females in STEMI were older (53.6 years in males compared to 58 years in females, P<0.001) and have greater atypical presentation (31.6% in females and 13.98% in males, P<0.001). Females also have higher mean time to presentation and higher incidence of diabetes, dyslipidemia, hypertension and high BMI, whereas males had higher incidence of smoking. Females are less likely to undergo thrombolysis (28.73% in females compared to 44.34% in males, p=0.04) and revascularization (17.5% in males and 9.1% in females p-0.01) during index hospitalization, but standard medical therapy was similar. Women were also more likely to develop heart failure either at presentation or at 30 days and also had a higher 30-day mortality (15.5% in female and 9.8% in male, p value-0.06).\u0000Conclusion: This study represents the first reported study on impact of gender on clinical presentation of STEMI from North-Eastern India and has observed that females have a higher mean age of presentation, higher incidence of atypical presentation, diabetes, dyslipidemia, hypertension and high BMI. Females also present later than males, though statistically not significant and also less likely to receive thrombolysis and revascularization than males. The 30-day mortality was also higher in females.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46131720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：